Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,EGFR N	SA00058915	47	F	SA00058915
Ordering Phys CLIENT,CLIENT				**DOB** 06/10/1966
Client Order # SA00058915	**Account Information**			**Report Notes**
Collected 06/10/2013 00:00	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 06/12/2013 09:46				

Test	Flag	Results	Unit	Reference Value	Perform Site*
EGFR Gene, Mutation Analysis, Tumor					
RECEIVED: 06/11/2013 12:04 **REPORTED:** 06/11/2013 17:05					
Specimen		Tissue-Tumor			MCR
Specimen ID		1062170			MCR
Order Date		11 Jun 2013 13:12			MCR
Reason for Referral					MCR
Evaluate tumor DNA for presence of a mutation in exons 18-21 of the EGFR gene.					
Method					MCR
Microscopic examination was performed by a pathologist to identify areas of tumor for enrichment by macrodissection. A PCR based assay employing allele specific amplification was used to test for the presence of 29 mutations within exons 18-21 of the EGFR gene (G719A, G719S, G719C in exon 18; small deletions in exon 19; T790M, S768I, and small insertions in exon 20; and L858R and L861Q in exon 21). Mutation nomenclature is based on GenBank accession number; NM005228.3.					
Result					MCR
Tumor type: Lung Adenocarcinoma					
EGFR status: Wild-type					
Interpretation					MCR
Current data suggest that patients with non-small cell lung cancer with mutations in the tyrosine kinase domain (exons 18-21) of EGFR may respond to EGFR tyrosine kinase inhibitor therapies. Thus, the absence of an EGFR mutation within this tumor specimen suggests that these therapies may have limited therapeutic value for this patient.					
The predictive value of EGFR testing applies to EGFR tyrosine kinase inhibitor therapies, not to other therapeutic agents.					
This result does not rule out the presence of a mutation that may be present but below the limits of detection for this assay (approximately 5%) or an EGFR mutation that is not part of this panel. It is estimated that this panel detects greater than 95% of pathogenic mutations (exons 18-21) associated with response/resistance to EGFR-targeted therapies.					
Consideration of these results, in light of other clinical information, may aid in clinical management decisions for this patient.					

Performing Site Legend on Last Page of Report

* Report times for Mayo performed tests are CST/CDT

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,EGFR N	SA00058915	47	F	SA00058915
Ordering Phys CLIENT,CLIENT				**DOB** 06/10/1966
Client Order # SA00058915	**Account Information**			**Report Notes**
Collected 06/10/2013 00:00	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 06/12/2013 09:46				

Test	Flag	Results	Unit	Reference Value	Perform Site*

CAUTIONS:
Rare polymorphisms exist that could lead to false negative or false positive results. Test results should be interpreted in context of clinical findings, tumor sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Laboratory developed test.

Reviewed By:	Benjamin Robert Kipp	MCR
Release Date	11 Jun 2013 17:04	MCR

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: